Vasoptic raises $250,000 from Abell Foundation

February 25, 2016

Baltimore medical device startup Vasoptic Medical Inc. has raised $250,000 from the Abell Foundation Inc. to continue development of its eye imaging technology.

 

The new funding adds to Abell’s previous $250,000 investment and will serve as a bridge to the larger Series A round Vasoptic plans to raise later this year, said Vasoptic CEO M. Jason Brooke.

 

The money will support Vasoptic as it embarks on the first human clinical trial of its eye imaging technology. A human trial is an important step in the path to commercialization and, with positive results, will help Vasoptic attract investors for its Series A round.

 

Vasoptic is developing eye imaging technology that can be used to help doctors detect certain eye conditions, such as diabetic retinopathy, a condition that can lead to vision impairment and blindness among diabetics if untreated. Vasoptic’s technology is designed to allow doctors to examine a patient’s retina without having to dilate the pupil or add dye and could therefore be more readily used at primary care centers, pharmacies and clinics.

 

For full story click here.

Share on Facebook
Share on Twitter
Please reload

Recent News

Vasoptic Medical impresses at ARVO 2017

May 15, 2017

Vasoptic Medical's $1.5 million cash infusion pushes it toward FDA approval

April 25, 2017

Early Detection: New Device Measures Risk of Blindness from Diabetes

October 7, 2016

1/10
Please reload

© 2020 Vasoptic Medical Inc.

1215 E. Fort Ave Suite 304
Baltimore, MD 21230